Lori MBA - Axsome Therapeutics Executive Development
| AXSM Stock | USD 99.08 0.86 0.88% |
Executive
Lori MBA is Executive Development of Axsome Therapeutics
| Age | 46 |
| Address | One World Trade Center, New York, NY, United States, 10007 |
| Phone | 212 332 3241 |
| Web | https://www.axsome.com |
Axsome Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2644) % which means that it has lost $0.2644 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7161) %, meaning that it created substantial loss on money invested by shareholders. Axsome Therapeutics' management efficiency ratios could be used to measure how well Axsome Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 3rd of December 2024, Return On Tangible Assets is likely to drop to -0.48. In addition to that, Return On Capital Employed is likely to drop to -0.54. At this time, Axsome Therapeutics' Other Assets are very stable compared to the past year. As of the 3rd of December 2024, Intangibles To Total Assets is likely to grow to 0.18, while Return On Tangible Assets are likely to drop (0.48).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Morneau | Viking Therapeutics | 59 | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Shannon Kelley | Madrigal Pharmaceuticals | N/A | |
| Rob Ackles | ACADIA Pharmaceuticals | N/A | |
| Kianoush Motesharei | Madrigal Pharmaceuticals | ||
| David Ege | Seres Therapeutics | 50 | |
| Erika Zavod | ACADIA Pharmaceuticals | N/A | |
| Kirk MD | PDS Biotechnology Corp | 72 | |
| Patrick Lamy | Akero Therapeutics | 51 | |
| Gina JD | Amylyx Pharmaceuticals | 53 | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| Sheila Denton | Incyte | 58 | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| Ariel Hurley | Blueprint Medicines Corp | 50 | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Albert Kildani | ACADIA Pharmaceuticals | N/A | |
| Pamela Murphy | Incyte | 73 | |
| Gregory Conn | PDS Biotechnology Corp | 69 | |
| Catriona Yale | Akero Therapeutics | 52 | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
| RPh Young | Seres Therapeutics | 57 | |
Management Performance
| Return On Equity | -1.72 | ||||
| Return On Asset | -0.26 |
Axsome Therapeutics Leadership Team
Elected by the shareholders, the Axsome Therapeutics' board of directors comprises two types of representatives: Axsome Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axsome. The board's role is to monitor Axsome Therapeutics' management team and ensure that shareholders' interests are well served. Axsome Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axsome Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hunter Esq, General Secretary | ||
| Herriot MD, Founder, Chairman and CEO | ||
| Amanda PharmD, Senior Development | ||
| Mark Jacobson, Senior Director - Operations | ||
| Lori MBA, Executive Development | ||
| Kevin PharmD, Ex Strategy | ||
| Mark MA, Chief Officer | ||
| Ari Maizel, Executive Commercial | ||
| MB CPA, Director Finance |
Axsome Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axsome Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.72 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (0.92) % | ||||
| Operating Margin | (0.44) % | ||||
| Current Valuation | 4.67 B | ||||
| Shares Outstanding | 48.46 M | ||||
| Shares Owned By Insiders | 16.67 % | ||||
| Shares Owned By Institutions | 81.07 % | ||||
| Number Of Shares Shorted | 7.69 M | ||||
| Price To Earning | (3.34) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.58) | Revenue Per Share 7.108 | Quarterly Revenue Growth 0.813 | Return On Assets (0.26) | Return On Equity (1.72) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.